Immunotherapy has revolutionised cancer therapy for specific tumour types. The dismal prognosis of melanoma patients with advanced stage has improved but remains poor. With the increasing use of these monoclonal antibodies, toxicities are becoming more prevalent. Neurological adverse events are still rare but have an enormous impact on the continuum of care. This study reports a case of a 70-year-old man with stage IIIc melanoma who presented with cerebral vasculitis after rechallenge therapy with ipilimumab/nivolumab.
(Belg J Med Oncol 2023;17(4):128–31)